bottom line equal weight rate reflect
lack convict exceed organ sale growth
durabl expand margin report ahead forecast
upsiz guidanc challeng view
opportun shine quarter main risk
modest growth forecast compani discuss
bevi opportun compani acceler growth
come quarter put emphasi intern
runway ahead ou molecular busi see
increas legitim possibl well intern
market sit well us counterpart market share
compani see multi-year growth driver opportun work
toward share gain still see mani holx
busi growth challeng mammographi capit equip
skelet health busi growth asset cytolog
perinat busi remain declin juri whether
surgic growth busi opportun highlight
pose risk view under-perform busi
challeng achiev msd organ framework
subsid margin headwind shift profit new
normal secondari focu accret quarter
expect improv gross margin
partial geo product mix mainli due subsid
cynosur headwind weigh perform
recent under-perform segment blend
number go forward compani experi step
profit new normal level sever point higher recent
histor result anticip major margin
improv near mid-term compani primari
focu current growth acceler margin secondari
model updat roll result incorpor
manag guidanc updat view adjust
estim note
herein maintain equal weight rate target price
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud intang acquir amort depreci
purchas account restructur charg one time charg
non-gaap ep exclud acquisit restructur one time relat charg
non-gaap ep exclud acquisit restructur one time relat charg
non-gaap ep exclud acquisit restructur one time relat charg
compani data secur llc estim reuter
price target nc
price target reflect enterpris valu use project level debt cash
ebitda ex option multipl discount median ev/ebitda multipl
devic peer group believ reason given structur growth challeng downsid
risk equal weight rate includ limit follow factor first slowdown
demand capit equip hospit would limit potenti futur growth secondli
extens cervic cancer screen interv would neg impact
downsid risk includ potenti increas competit molecular diagnost acquisit target
select integr
upsid risk equal weight includ improv demand hospit addit expans
cervic cancer screen interv limit competit molecular diagnost well faster
expect margin improv across busi line could lead increas investor appetit stand
upsid risk rate
equal weight rate reflect lack convict exceed
organ sale growth durabl expand margin
inc medic equip suppli diagnost devic manufactur domin
market share billion world-wide mammographi market estim market share
million cervic cancer screen market estim share
compani oper four segment breast care revenu diagnost
revenu gyn surgic revenu skelet health revenu
compani gener billion corpor revenu million net profit septemb
